Public health experts are debating how to help the 1 million children in the Philippines who received a new vaccine against dengue that could, in rare cases, sicken rather than protect them

Quick Read

The Food and Drug Administration has agreed to consider Sanofi Pasteur’s application for Dengvaxia, the world’s first licensed vaccine that protects against dengue but one that brings with it considerable controversy and concern

Quick Read

Sanofi revealed in November that Dengvaxia – the world’s first dengue vaccine – might increase the risk of severe disease in people who had never been exposed to the virus. The news prompted an uproar in the Philippines, where more than 800,000 school-age children had been vaccinated

Quick Read